Clinical trial
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients…
NCT00143312 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00143312 |
|---|---|
| Title | Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants |
| Official title | Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT). |
| Acronym | VOSIFI |
| Lead sponsor | Pfizer, Industry |
| Collaborators | European Society for Blood and Marrow Transplantation |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prophylaxis Of Invasive Fungal Infections |
| Intervention type | Drug |
| Interventions | voriconazole |
| Enrollment | 45 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Oct 6, 2009 |
| Countries | Belgium, France, Germany, Portugal, Spain, Sweden, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: